These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

838 related items for PubMed ID: 25652176

  • 1. Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer.
    Santarpia M, Altavilla G, Rosell R.
    Expert Rev Respir Med; 2015 Jun; 9(3):255-68. PubMed ID: 25652176
    [Abstract] [Full Text] [Related]

  • 2. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH.
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [Abstract] [Full Text] [Related]

  • 3. Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer.
    Wong KM, Noonan S, O'Bryant C, Jimeno A.
    Drugs Today (Barc); 2015 Mar; 51(3):161-70. PubMed ID: 25876560
    [Abstract] [Full Text] [Related]

  • 4. Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.
    McKeage K.
    Drugs; 2015 Jan; 75(1):75-82. PubMed ID: 25428710
    [Abstract] [Full Text] [Related]

  • 5. Alectinib for treatment of ALK-positive non-small-cell lung cancer.
    Avrillon V, Pérol M.
    Future Oncol; 2017 Feb; 13(4):321-335. PubMed ID: 27780368
    [Abstract] [Full Text] [Related]

  • 6. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.
    Gainor JF, Sherman CA, Willoughby K, Logan J, Kennedy E, Brastianos PK, Chi AS, Shaw AT.
    J Thorac Oncol; 2015 Feb; 10(2):232-6. PubMed ID: 25526238
    [Abstract] [Full Text] [Related]

  • 7. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.
    Ignatius Ou SH, Azada M, Hsiang DJ, Herman JM, Kain TS, Siwak-Tapp C, Casey C, He J, Ali SM, Klempner SJ, Miller VA.
    J Thorac Oncol; 2014 Apr; 9(4):549-53. PubMed ID: 24736079
    [Abstract] [Full Text] [Related]

  • 8. Alectinib for ALK-positive non-small-cell lung cancer.
    Rossi A.
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1005-13. PubMed ID: 27232673
    [Abstract] [Full Text] [Related]

  • 9. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
    Ou SH, Greenbowe J, Khan ZU, Azada MC, Ross JS, Stevens PJ, Ali SM, Miller VA, Gitlitz B.
    Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
    [Abstract] [Full Text] [Related]

  • 10. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
    Yoshimura Y, Kurasawa M, Yorozu K, Puig O, Bordogna W, Harada N.
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):623-8. PubMed ID: 26849637
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
    Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T.
    Lancet; 2017 Jul 01; 390(10089):29-39. PubMed ID: 28501140
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.
    Ou SH, Milliken JC, Azada MC, Miller VA, Ali SM, Klempner SJ.
    Lung Cancer; 2016 Jan 01; 91():70-2. PubMed ID: 26464158
    [Abstract] [Full Text] [Related]

  • 16. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
    Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, Mekhail T, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, Kim DW.
    J Clin Oncol; 2016 Mar 01; 34(7):661-8. PubMed ID: 26598747
    [Abstract] [Full Text] [Related]

  • 17. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
    Katayama R, Friboulet L, Koike S, Lockerman EL, Khan TM, Gainor JF, Iafrate AJ, Takeuchi K, Taiji M, Okuno Y, Fujita N, Engelman JA, Shaw AT.
    Clin Cancer Res; 2014 Nov 15; 20(22):5686-96. PubMed ID: 25228534
    [Abstract] [Full Text] [Related]

  • 18. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
    Goto Y, Yamamoto N, Masters ET, Kikkawa H, Mardekian J, Wiltshire R, Togo K, Ohe Y.
    Adv Ther; 2020 Jul 15; 37(7):3311-3323. PubMed ID: 32472430
    [Abstract] [Full Text] [Related]

  • 19. The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer.
    Srinivasamaharaj S, Salame BK, Rios-Perez J, Kloecker G, Perez CA.
    Expert Rev Anticancer Ther; 2016 Dec 15; 16(12):1227-1233. PubMed ID: 27744726
    [Abstract] [Full Text] [Related]

  • 20. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
    Toyokawa G, Seto T.
    Clin Lung Cancer; 2014 Sep 15; 15(5):313-9. PubMed ID: 24984564
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.